UNLABELLED: The Centers for Medicare and Medicaid Services (CMS) has provided a mechanism for expanded coverage of selected promising technologies under its "coverage with evidence development (CED)" policy. The National Oncologic PET Registry (NOPR) was designed to address the CED requirements for collection of clinical and demographic data to allow for CMS coverage of PET for previously noncovered cancer types and indications. The NOPR opened in May 2006. This report reviews the NOPR's data collection and analysis plan. METHODS: NOPR is a nationwide prospective internet-based registry. All PET facilities that are participating providers in the Medicare program may enroll in NOPR. The PET facility is responsible for collecting and entering patient data into the NOPR database through a Web application at: (http://www.cancerPETregistry.org/). Data are collected from the requesting physician on Pre-PET and Post-PET forms. The primary research goal is to assess the effect of PET on referring physicians' plans of intended patient management across the spectrum of expanded cancer indications (diagnosis, staging, restaging, suspected recurrence, and treatment monitoring). The NOPR investigators will have access to data only on cases in which both the patient and the referring physician have consented to allow their data to be used for research. Data will be analyzed and compared in aggregate for all cancers by category (e.g., staging) and then for specific high-impact types and indications (e.g., staging of pancreatic cancer) when 200 patients have been accrued to a specific combination or after the NOPR has been operational for 1 y. CONCLUSION: The NOPR will allow an accurate assessment of the impact of PET on intended patient management across a wide spectrum of cancer indications.
UNLABELLED: The Centers for Medicare and Medicaid Services (CMS) has provided a mechanism for expanded coverage of selected promising technologies under its "coverage with evidence development (CED)" policy. The National Oncologic PET Registry (NOPR) was designed to address the CED requirements for collection of clinical and demographic data to allow for CMS coverage of PET for previously noncovered cancer types and indications. The NOPR opened in May 2006. This report reviews the NOPR's data collection and analysis plan. METHODS: NOPR is a nationwide prospective internet-based registry. All PET facilities that are participating providers in the Medicare program may enroll in NOPR. The PET facility is responsible for collecting and entering patient data into the NOPR database through a Web application at: (http://www.cancerPETregistry.org/). Data are collected from the requesting physician on Pre-PET and Post-PET forms. The primary research goal is to assess the effect of PET on referring physicians' plans of intended patient management across the spectrum of expanded cancer indications (diagnosis, staging, restaging, suspected recurrence, and treatment monitoring). The NOPR investigators will have access to data only on cases in which both the patient and the referring physician have consented to allow their data to be used for research. Data will be analyzed and compared in aggregate for all cancers by category (e.g., staging) and then for specific high-impact types and indications (e.g., staging of pancreatic cancer) when 200 patients have been accrued to a specific combination or after the NOPR has been operational for 1 y. CONCLUSION: The NOPR will allow an accurate assessment of the impact of PET on intended patient management across a wide spectrum of cancer indications.
Authors: Benedikt J Schwaiger; David L Kopperdahl; Lorenzo Nardo; Luca Facchetti; Alexandra S Gersing; Jan Neumann; Kwang J Lee; Tony M Keaveny; Thomas M Link Journal: Bone Date: 2017-04-24 Impact factor: 4.398
Authors: Rathan M Subramaniam; Anthony F Shields; Archana Sachedina; Lucy Hanna; Fenghai Duan; Barry A Siegel; Bruce E Hillner Journal: Oncologist Date: 2016-07-08
Authors: Christina Pfannenberg; Brigitte Gueckel; Lisa Wang; Sergios Gatidis; Susann-Cathrin Olthof; Werner Vach; Matthias Reimold; Christian la Fougere; Konstantin Nikolaou; Peter Martus Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-29 Impact factor: 9.236
Authors: Ilana F Gareen; Bruce E Hillner; Lucy Hanna; Rajesh Makineni; Fenghai Duan; Anthony F Shields; Rathan M Subramaniam; Barry A Siegel Journal: J Nucl Med Date: 2017-12-28 Impact factor: 10.057